These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 22691713

  • 1. Blonanserin, a novel atypical antipsychotic agent not actively transported as substrate by P-glycoprotein.
    Inoue T, Osada K, Tagawa M, Ogawa Y, Haga T, Sogame Y, Hashizume T, Watanabe T, Taguchi A, Katsumata T, Yabuki M, Yamaguchi N.
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Oct 01; 39(1):156-62. PubMed ID: 22691713
    [Abstract] [Full Text] [Related]

  • 2. In vitro to in vivo comparison of the substrate characteristics of sorafenib tosylate toward P-glycoprotein.
    Gnoth MJ, Sandmann S, Engel K, Radtke M.
    Drug Metab Dispos; 2010 Aug 01; 38(8):1341-6. PubMed ID: 20413726
    [Abstract] [Full Text] [Related]

  • 3. In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system.
    Feng B, Mills JB, Davidson RE, Mireles RJ, Janiszewski JS, Troutman MD, de Morais SM.
    Drug Metab Dispos; 2008 Feb 01; 36(2):268-75. PubMed ID: 17962372
    [Abstract] [Full Text] [Related]

  • 4. In vitro P-glycoprotein efflux inhibition by atypical antipsychotics is in vivo nicely reflected by pharmacodynamic but less by pharmacokinetic changes.
    Schmitt U, Kirschbaum KM, Poller B, Kusch-Poddar M, Drewe J, Hiemke C, Gutmann H.
    Pharmacol Biochem Behav; 2012 Aug 01; 102(2):312-20. PubMed ID: 22525746
    [Abstract] [Full Text] [Related]

  • 5. Pluronic P85 enhances the delivery of digoxin to the brain: in vitro and in vivo studies.
    Batrakova EV, Miller DW, Li S, Alakhov VY, Kabanov AV, Elmquist WF.
    J Pharmacol Exp Ther; 2001 Feb 01; 296(2):551-7. PubMed ID: 11160643
    [Abstract] [Full Text] [Related]

  • 6. Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux.
    Dai H, Marbach P, Lemaire M, Hayes M, Elmquist WF.
    J Pharmacol Exp Ther; 2003 Mar 01; 304(3):1085-92. PubMed ID: 12604685
    [Abstract] [Full Text] [Related]

  • 7. Effect of P-glycoprotein on intestinal absorption and brain penetration of antiallergic agent bepotastine besilate.
    Ohashi R, Kamikozawa Y, Sugiura M, Fukuda H, Yabuuchi H, Tamai I.
    Drug Metab Dispos; 2006 May 01; 34(5):793-9. PubMed ID: 16455807
    [Abstract] [Full Text] [Related]

  • 8. Role of P-glycoprotein in accumulation and cytotoxicity of amrubicin and amrubicinol in MDR1 gene-transfected LLC-PK1 cells and human A549 lung adenocarcinoma cells.
    Hira A, Watanabe H, Maeda Y, Yokoo K, Sanematsu E, Fujii J, Sasaki J, Hamada A, Saito H.
    Biochem Pharmacol; 2008 Feb 15; 75(4):973-80. PubMed ID: 18054347
    [Abstract] [Full Text] [Related]

  • 9. Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
    Bundgaard C, Jensen CJ, Garmer M.
    Drug Metab Dispos; 2012 Mar 15; 40(3):461-6. PubMed ID: 22112383
    [Abstract] [Full Text] [Related]

  • 10. Pharmacodynamic consequences of P-glycoprotein-dependent pharmacokinetics of risperidone and haloperidol in mice.
    Kirschbaum KM, Henken S, Hiemke C, Schmitt U.
    Behav Brain Res; 2008 Apr 09; 188(2):298-303. PubMed ID: 18164477
    [Abstract] [Full Text] [Related]

  • 11. The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein.
    Wang JS, Ruan Y, Taylor RM, Donovan JL, Markowitz JS, DeVane CL.
    Int J Neuropsychopharmacol; 2004 Dec 09; 7(4):415-9. PubMed ID: 15683552
    [Abstract] [Full Text] [Related]

  • 12. Risperidone and paliperidone inhibit p-glycoprotein activity in vitro.
    Zhu HJ, Wang JS, Markowitz JS, Donovan JL, Gibson BB, DeVane CL.
    Neuropsychopharmacology; 2007 Apr 09; 32(4):757-64. PubMed ID: 16936711
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein.
    Wang JS, Zhu HJ, Markowitz JS, Donovan JL, DeVane CL.
    Psychopharmacology (Berl); 2006 Sep 09; 187(4):415-23. PubMed ID: 16810505
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics of acute and sub-chronic aripiprazole in P-glycoprotein deficient mice.
    Kirschbaum KM, Uhr M, Holthoewer D, Namendorf C, Pietrzik C, Hiemke C, Schmitt U.
    Neuropharmacology; 2010 Nov 09; 59(6):474-9. PubMed ID: 20599439
    [Abstract] [Full Text] [Related]

  • 15. P-glycoprotein efflux at the blood-brain barrier mediates differences in brain disposition and pharmacodynamics between two structurally related neurokinin-1 receptor antagonists.
    Smith BJ, Doran AC, McLean S, Tingley FD, O'Neill BT, Kajiji SM.
    J Pharmacol Exp Ther; 2001 Sep 09; 298(3):1252-9. PubMed ID: 11504828
    [Abstract] [Full Text] [Related]

  • 16. Effect of novel atypical antipsychotic, blonanserin, on extracellular neurotransmitter level in rat prefrontal cortex.
    Ohoyama K, Yamamura S, Hamaguchi T, Nakagawa M, Motomura E, Shiroyama T, Tanii H, Okada M.
    Eur J Pharmacol; 2011 Feb 25; 653(1-3):47-57. PubMed ID: 21147094
    [Abstract] [Full Text] [Related]

  • 17. Differential involvement of multidrug resistance-associated protein 1 and P-glycoprotein in tissue distribution and excretion of grepafloxacin in mice.
    Sasabe H, Kato Y, Suzuki T, Itose M, Miyamoto G, Sugiyama Y.
    J Pharmacol Exp Ther; 2004 Aug 25; 310(2):648-55. PubMed ID: 15131241
    [Abstract] [Full Text] [Related]

  • 18. Blood-brain barrier (BBB) pharmacoproteomics: reconstruction of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and brain in mice.
    Uchida Y, Ohtsuki S, Kamiie J, Terasaki T.
    J Pharmacol Exp Ther; 2011 Nov 25; 339(2):579-88. PubMed ID: 21828264
    [Abstract] [Full Text] [Related]

  • 19. In vivo and in vitro myocardial binding of risperidone and 9-hydroxyrisperidone.
    Titier K, Déridet E, Moore N.
    Toxicol Appl Pharmacol; 2002 Apr 15; 180(2):145-9. PubMed ID: 11969382
    [Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics and pharmacodynamics of alfentanil in P-glycoprotein-competent and P-glycoprotein-deficient mice: P-glycoprotein efflux alters alfentanil brain disposition and antinociception.
    Kalvass JC, Olson ER, Pollack GM.
    Drug Metab Dispos; 2007 Mar 15; 35(3):455-9. PubMed ID: 17178769
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.